RecruitingNot ApplicableNCT06268600
The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma
The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma: A Retrospective Study
Sponsor
Jiangxi Provincial Cancer Hospital
Enrollment
320 participants
Start Date
Jan 1, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
This study aimed to reduce radiation-induced thyroid injury without compromising control of the cervical region by optimizing the delineation of the cervical lymph node drainage area.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria12
- The pathological diagnosis was newly diagnosed non-keratinizing squamous cell carcinoma nasopharyngeal carcinoma.
- The clinical stage is T1-4N0-3M0 (stage I\~IVa, UICC/AJCC 8th edition);
- There is no history of hypothyroidism or hyperthyroidism before treatment;
- Using intensity-modulated radiotherapy technology,
- Complete radical dose radiotherapy;
- KPS≥70 points;
- Age 18-70 years old;
- Male or female who is not pregnant or lactating;
- Hematological examination: white blood cells \> 4×109/L, neutrophils \> 2×109/L, hemoglobin \> 90g/L, platelets \> 100×109/L;
- Liver function: ALT, AST \< 1.5×ULN, ALP \< 2.5×ULN, bilirubin \< ULN.
- Renal function: creatinine \> 60 ml/min;
- The patient signs the informed consent form;
Exclusion Criteria7
- WHO pathological classification is keratinizing squamous cell carcinoma or basaloid carcinoma;
- palliative treatment;
- Have a history of other malignant tumors;
- Pregnant or lactating women (women of childbearing age should consider taking a pregnancy test, and patients are required to use effective contraception during treatment);
- Have a history of neck surgery;
- Have a history of hyperthyroidism or hypothyroidism.
- Previous history of head and neck radiation therapy;
Interventions
RADIATIONModified neck target volume delineation
Modified neck target volume delineation method was used to define the inner boundary of regions III and IVa as the outer edge of the common carotid artery.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06268600
Related Trials
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT059417413 locations
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT0623972726 locations
Comorbidities Resolution After MGB Surgery and Change in Body Composition
NCT060156201 location
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
NCT060592611 location
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
NCT065925991 location